# MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

> **NCT00533312** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 407 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks
- **DRUG:** MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks
- **DRUG:** Comparator : niacin / Duraton of Treatment: 4 Weeks

## Key facts

- **NCT ID:** NCT00533312
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-07
- **Final completion:** 2007-01
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533312, "MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00533312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*